Natural Alternatives International, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended June 30, 2013, compared with fiscal 2012. Although the request metadata says “2012 Q4,” this filing reports annual results; the supplied text does not provide a clear standalone fourth-quarter financial summary. Amounts below are in U.S. dollars unless stated otherwise.
Business context and reporting period
NAI formulates and manufactures private-label nutritional supplements, licenses beta-alanine-related intellectual property under the CarnoSyn brand, and sells its Pathway to Healing branded products. Contract manufacturing generated 90% of FY2013 revenue. The company operates in the United States and Switzerland.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Net sales | $62.8 million | $72.8 million |
| Gross profit / margin | $11.8 million / 18.7% | $15.5 million / 21.2% |
| Operating income / margin | $2.2 million / 3.4% | $6.2 million / 8.5% |
| Net income | $1.6 million | $4.2 million |
| Diluted earnings per share | $0.23 | $0.59 |
| Cash from operating activities | $4.5 million | $1.7 million |
| Capital expenditures | $1.6 million | $2.3 million |
Cash and cash equivalents were $16.7 million at June 30, 2013, compared with $14.5 million a year earlier. The company reported no outstanding debt and $5.5 million available under credit facilities. Current assets were $35.3 million and current liabilities $5.9 million. Management said available cash and expected operating cash flow should cover working capital needs and capital expenditures for at least 12 months.
Material changes versus the prior comparable period
- Revenue fell 13.8%. Private-label manufacturing sales declined 10.4%, mainly from lower volumes, lower prices on some high-volume products, and less favorable euro exchange rates.
- Revenue from patent and trademark licensing fell 40% to $4.8 million, largely because FY2012 included $3.4 million of beta-alanine raw-material sales; FY2013 raw-material sales were $103,000. Royalty income rose 2% to $4.7 million.
- Branded-products sales declined 15.2% to $1.3 million as Pathway to Healing sales softened.
- Gross margin contracted 2.5 percentage points. Management cited lower manufacturing volumes and prices, higher per-unit production costs, labor and overhead effects, and branded-product sales mix and inventory write-offs.
- Operating income declined 65%, while net income fell 62%. SG&A rose 3.7% to $9.6 million, partly due to higher patent litigation and prosecution costs.
- Operating cash flow improved to $4.5 million, with a $2.0 million cash benefit from accounts receivable changes, versus a $5.5 million use in FY2012. Inventory increased by $1.7 million and used cash.
Outlook, risks, contingencies, and unusual items
- Management anticipated net income in FY2014, but gave no earnings or revenue range and cautioned there was no assurance. It expected CarnoSyn licensing and related revenue to expand and anticipated lower revenue concentration from the two largest manufacturing customers as new and existing customers contributed sales.
- Raw-material availability, pricing, labor, and transportation costs were expected to remain challenging in FY2014. The company also identified beta-alanine supply dependence and potential interruptions as risks.
- Customer concentration remains significant: NSA represented about 50% and Mannatech about 19% of FY2013 private-label manufacturing sales. The NSA agreement was due to expire April 1, 2014; the filing says either party may terminate on three months’ written notice or for default.
- NAI incurred approximately $2.3 million in patent litigation and prosecution expense in FY2013 and estimated FY2014 costs of $1.0–$1.5 million. Patent disputes and re-examinations were pending; adverse findings could materially affect the beta-alanine business. The company also faced two product-liability suits relating to products it said it did not manufacture, distribute, or sell; dismissal motions were pending.
- Abbott could terminate its beta-alanine license agreement through December 1, 2013. Further license fees and royalties were therefore uncertain. The filing reported certain milestone payments collected, including one in July 2013 after year-end.
- Other material exposures include foreign-exchange movements, regulatory compliance, customer order timing, and dependence on a limited number of suppliers. The company had $14.1 million notional value of foreign-exchange contracts outstanding, maturing over the following 14 months.
- NAI reported effective disclosure controls and internal control over financial reporting as of June 30, 2013. The auditor issued an unqualified opinion on the financial statements; it did not attest to internal control effectiveness.
Most important facts for investors to verify
- Whether customer diversification and new orders offset continued weakness or pricing pressure in the core manufacturing business.
- Renewal and terms of the NSA agreement, and the evolution of NSA and Mannatech sales concentration.
- Actual FY2014 earnings, revenue, and margin performance versus management’s qualitative expectations.
- Outcomes and costs of patent litigation, patent re-examinations, and the Abbott agreement’s termination and payment conditions.
- Beta-alanine supply availability, licensing revenue durability, and the effect of raw-material and operating cost inflation.
- Cash conversion and inventory levels, given higher inventory and longer receivable collection times (45 days versus 30 days in FY2012).